MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 138.96% year-over-year to -$35.5 million in Q1 2026; TTM through Mar 2026 was $26.2 million, a 114.03% increase from a year earlier, with the FY2025 full-year figure at $153.0 million, up 156.48% from the prior year.
• Net Cash Flow retreated to -$35.5 million in Q1 2026 per MLTX's latest filing, from -$16.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $451.8 million in Q2 2023 and bottomed at -$195.7 million in Q4 2024.
• The 5-year median for Net Cash Flow is $7.2 million (2024), against an average of $17.0 million.
• Across the five-year window, Net Cash Flow sank 3266.85% in 2022 and soared 7962.69% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$1.7 million in 2022, then surged by 7962.69% to $132.9 million in 2023, then sank by 247.18% to -$195.7 million in 2024, then soared by 91.66% to -$16.3 million in 2025, then plunged by 117.93% to -$35.5 million in 2026.
• Per Business Quant, the three latest MLTX Net Cash Flow figures stand at -$35.5 million (Q1 2026), -$16.3 million (Q4 2025), and $44.3 million (Q3 2025).